Assessment of Patient with Breast Symptoms
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Burns, Surgical Treatment
Philippine College of Surgeons Dear PCS Fellows, We at the PCS Committee on HMO, RVS, & PHIC & The PCS Board of Regents are pleased to announce the Adoption of PAHMOC of our new & revised RVS. We are currently under negotiations with them with regard to the multiplier to be used to arrive at our final professional Fees. Rest assured that we will have a graduated & staggered increase of PF thru the years from what we are currently receiving due to the proposed yearly increments in the multiplier. To those Fellows who haven’t signed the USA (Universal Service Agreement found here in our PCS website) please be reminded to sign and submit to the PCS Secretariat, as only those who did and are in good standing (updated annual dues) will be eligible to avail of the benefits of the new RVS scale. Indeed, we are hoping & looking forward to a merrier 2020 Christmas for our Fellows. Yours truly, FERNANDO L. LOPEZ, MD, FPCS Chairman Noted by: JOSELITO M. MENDOZA, MD, FPCS Regent-in-Charge JOSE ANTONIO M. SALUD, MD, FPCS President For many years now the PCS Committee on HMO & RUV has been compiling, with the assistance of the different surgical subspecialties, a new updated list of RUV for each procedure to replace the existing manual of 2009. This new version not only has a more complete listing of cases but also includes the newly developed procedures particularly for all types of minimally invasive operations. Sometime last year, the Department of Health released Circular 2019-0558 on the Public Access to the Price Information by all Health Providers as required by Section 28.16 of the IRR of the Universal Health Care Act. -
BREAST IMAGING for SCREENING and DIAGNOSING CANCER Policy Number: DIAGNOSTIC 105.9 T2 Effective Date: January 1, 2017
Oxford UnitedHealthcare® Oxford Clinical Policy BREAST IMAGING FOR SCREENING AND DIAGNOSING CANCER Policy Number: DIAGNOSTIC 105.9 T2 Effective Date: January 1, 2017 Table of Contents Page Related Policies INSTRUCTIONS FOR USE .......................................... 1 Omnibus Codes CONDITIONS OF COVERAGE ...................................... 1 Preventive Care Services BENEFIT CONSIDERATIONS ...................................... 2 Radiology Procedures Requiring Precertification for COVERAGE RATIONALE ............................................. 3 eviCore Healthcare Arrangement APPLICABLE CODES ................................................. 5 DESCRIPTION OF SERVICES ...................................... 6 CLINICAL EVIDENCE ................................................. 7 U.S. FOOD AND DRUG ADMINISTRATION ................... 16 REFERENCES .......................................................... 18 POLICY HISTORY/REVISION INFORMATION ................ 22 INSTRUCTIONS FOR USE This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. When deciding coverage, the member specific benefit plan document must be referenced. The terms -
Breast Scintimammography
CLINICAL MEDICAL POLICY Policy Name: Breast Scintimammography Policy Number: MP-105-MD-PA Responsible Department(s): Medical Management Provider Notice Date: 11/23/2020 Issue Date: 11/23/2020 Effective Date: 12/21/2020 Next Annual Review: 10/2021 Revision Date: 09/16/2020 Products: Gateway Health℠ Medicaid Application: All participating hospitals and providers Page Number(s): 1 of 5 DISCLAIMER Gateway Health℠ (Gateway) medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions. POLICY STATEMENT Gateway Health℠ does not provide coverage in the Company’s Medicaid products for breast scintimammography. The service is considered experimental and investigational in all applications, including but not limited to use as an adjunct to mammography or in staging the axillary lymph nodes. This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person’s unique clinical circumstances warrant individual consideration, based upon review of applicable medical records. (Current applicable Pennsylvania HealthChoices Agreement Section V. Program Requirements, B. Prior Authorization of Services, 1. General Prior Authorization Requirements.) Policy No. MP-105-MD-PA Page 1 of 5 DEFINITIONS Prior Authorization Review Panel – A panel of representatives from within the Pennsylvania Department of Human Services who have been assigned organizational responsibility for the review, approval and denial of all PH-MCO Prior Authorization policies and procedures. Scintimammography A noninvasive supplemental diagnostic testing technology that requires the use of radiopharmaceuticals in order to detect tissues within the breast that accumulate higher levels of radioactive tracer that emit gamma radiation. -
Evaluation of Nipple Discharge
New 2016 American College of Radiology ACR Appropriateness Criteria® Evaluation of Nipple Discharge Variant 1: Physiologic nipple discharge. Female of any age. Initial imaging examination. Radiologic Procedure Rating Comments RRL* Mammography diagnostic 1 See references [2,4-7]. ☢☢ Digital breast tomosynthesis diagnostic 1 See references [2,4-7]. ☢☢ US breast 1 See references [2,4-7]. O MRI breast without and with IV contrast 1 See references [2,4-7]. O MRI breast without IV contrast 1 See references [2,4-7]. O FDG-PEM 1 See references [2,4-7]. ☢☢☢☢ Sestamibi MBI 1 See references [2,4-7]. ☢☢☢ Ductography 1 See references [2,4-7]. ☢☢ Image-guided core biopsy breast 1 See references [2,4-7]. Varies Image-guided fine needle aspiration breast 1 Varies *Relative Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate Radiation Level Variant 2: Pathologic nipple discharge. Male or female 40 years of age or older. Initial imaging examination. Radiologic Procedure Rating Comments RRL* See references [3,6,8,10,13,14,16,25- Mammography diagnostic 9 29,32,34,42-44,71-73]. ☢☢ See references [3,6,8,10,13,14,16,25- Digital breast tomosynthesis diagnostic 9 29,32,34,42-44,71-73]. ☢☢ US is usually complementary to mammography. It can be an alternative to mammography if the patient had a recent US breast 9 mammogram or is pregnant. See O references [3,5,10,12,13,16,25,30,31,45- 49]. MRI breast without and with IV contrast 1 See references [3,8,23,24,35,46,51-55]. -
Advanced Breast Imaging: MBI, ABUS, Tomo, CE-MRI, Fast-MRI, Breast PEM
Advanced Breast Imaging: MBI, ABUS, Tomo, CE-MRI, Fast-MRI, Breast PEM Thursday, May 2, 2019 7:00 AM-12:00 PM COURSE MODERATORS: Paul Baron, MD and Souzan El-Eid, MD FACULTY: Paul Baron, MD; Souzan El-Eid, MD; Ian Grady, MD; Alan Hollingsworth, MD; Jessica Leung, MD; Jocelyn Rapelyea, MD COURSE DESCRIPTION: Advances in breast imaging have been creating as much controversy as improvements in patient care. Is screening mammography still the standard of care for breast cancer screening? Should high-risk patients and/or patients with dense breasts undergo annual gadolinium-enhanced MRI, and how does “fast” MRI impact the risk, benefit, and cost balance? If you could acquire or utilize only one supplemental imaging modality, should you use whole-breast ultrasound (manual or automated), breast MRI, molecular breast imaging, or breast positron emission mammography, and what are the pros and cons of each? This course will focus on bringing the surgeon up to speed on current and emerging breast imaging modalities; screening for average-risk versus high-risk patients, with discussions of how various technologies work, the supporting data, and the economic implications. COURSE OBJECTIVES: At the conclusion of this course, participants should be able to: • Identify current treatment and management options for breast cancer patients • Discuss the pros and cons of available screening modalities • Determine the optimal screening regimen for average-risk and high-risk patients This course will offer participants an opportunity to become familiar with -
For Dense Breast Cancer Screening Integrated to Mammography: Effectiveness, Performance and Detection Rates
Journal of Personalized Medicine Article Second-Generation 3D Automated Breast Ultrasonography (Prone ABUS) for Dense Breast Cancer Screening Integrated to Mammography: Effectiveness, Performance and Detection Rates Gianluca Gatta 1 , Salvatore Cappabianca 1, Daniele La Forgia 2,* , Raffaella Massafra 2, Annarita Fanizzi 2, Vincenzo Cuccurullo 1 , Luca Brunese 3, Alberto Tagliafico 4 and Roberto Grassi 1 1 Dipartimento di Medicina di Precisione Università della Campania “Luigi Vanvitelli”, 80131 Napoli, Italy; [email protected] (G.G.); [email protected] (S.C.); [email protected] (V.C.); [email protected] (R.G.) 2 IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy; [email protected] (R.M.); [email protected] (A.F.) 3 Dipartimento di Medicina e Scienze della Salute “Vincenzo Tiberio”—Università degli Studi del Molise, 86100 Campobasso, Italy; [email protected] 4 Department of Health Sciences, University of Genoa, 16126 Genoa, Italy; alberto.tagliafi[email protected] * Correspondence: [email protected]; Tel.: +39-80-5555111 Abstract: In our study, we added a three-dimensional automated breast ultrasound (3D ABUS) to Citation: Gatta, G.; Cappabianca, S.; mammography to evaluate the performance and cancer detection rate of mammography alone or La Forgia, D.; Massafra, R.; Fanizzi, A.; Cuccurullo, V.; Brunese, L.; with the addition of 3D prone ABUS in women with dense breasts. Our prospective observational Tagliafico, A.; Grassi, R. study was based on the screening of 1165 asymptomatic women with dense breasts who selected Second-Generation 3D Automated independent of risk factors. The results evaluated include the cancers detected between June 2017 Breast Ultrasonography (Prone and February 2019, and all surveys were subjected to a double reading. -
Breast Cancer Screening and Chemoprevention
Management of Breast Diseases Ismail Jatoi Manfred Kaufmann (Eds.) Management of Breast Diseases Dr. Ismail Jatoi Prof. Dr. Manfred Kaufmann Head, Breast Care Center Breast Unit National Naval Medical Center Director, Women’s Hospital Uniformed Services University University of Frankfurt of the Health Sciences Theodor-Stern-Kai 7 4301 Jones Bridge Rd. 60590 Frankfurt Bethesda, MD 20814 Germany USA [email protected] [email protected] ISBN: 978-3-540-69742-8 e-ISBN: 978-3-540-69743-5 DOI: 10.1007/978-3-540-69743-5 Springer Heidelberg Dordrecht London New York Library of Congress Control Number: 2009934509 © Springer-Verlag Berlin Heidelberg 2010 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer. Violations are liable to prosecution under the German Copyright Law. The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specifi c statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product liability: The publishers cannot guarantee the accuracy of any information about dosage and appli- cation contained in this book. -
Breast Imaging Faqs
Breast Imaging Frequently Asked Questions Update 2021 The following Q&As address Medicare guidelines on the reporting of breast imaging procedures. Private payer guidelines may vary from Medicare guidelines and from payer to payer; therefore, please be sure to check with your private payers on their specific breast imaging guidelines. Q: What differentiates a diagnostic from a screening mammography procedure? Medicare’s definitions of screening and diagnostic mammography, as noted in the Centers for Medicare and Medicaid’s (CMS’) National Coverage Determination database, and the American College of Radiology’s (ACR’s) definitions, as stated in the ACR Practice Parameter of Screening and Diagnostic Mammography, are provided as a means of differentiating diagnostic from screening mammography procedures. Although Medicare’s definitions are consistent with those from the ACR, the ACR's definitions of screening and diagnostic mammography offer additional insight into what may be included in these procedures. Please go to the CMS and ACR Web site links noted below for more in- depth information about these studies. Medicare Definitions (per the CMS National Coverage Determination for Mammograms 220.4) “A diagnostic mammogram is a radiologic procedure furnished to a man or woman with signs and symptoms of breast disease, or a personal history of breast cancer, or a personal history of biopsy - proven benign breast disease, and includes a physician's interpretation of the results of the procedure.” “A screening mammogram is a radiologic procedure furnished to a woman without signs or symptoms of breast disease, for the purpose of early detection of breast cancer, and includes a physician’s interpretation of the results of the procedure. -
Breast Density and Automated Whole Breast Ultrasound
Breast Density and Automated Whole Breast Ultrasound EFW Radiology Medical Brief Dr. Tracy Elliot, MD, FRCP(c), HBSc Cardiothoracic & Breast Imaging Radiologist Clinical Assistant Professor Faculty of Medicine, University of Calgary November 2013 Breast Density and Automated Whole Breast Ultrasound EFW Radiology Medical Brief Most breast cancers (70-80%) occur in patients with no identifiable risk factors. Population based screening with mammography is therefore an essential primary strategy to reduce mortality from breast cancer. While mammography performs very well in fatty breasts, sensitivity is lower in dense, fibrous breasts. This is an intrinsic limitation of the mammogram which is the summation of a 3D volume into a 2D image. In the absence of intrinsic tissue contrast (provided by fat), lesions and parenchyma which have similar density overlap making detection more challenging. In addition, it is more difficult for the technologist to position for deep tissue due to loss of the normal retro- mammary fat zone. The reduced mammographic sensitivity in dense tissue is reflected by a higher interval cancer rate (odds ratio for interval cancer of 17.8 compared to fatty tissue in one study),1 larger size and more advanced stage at diagnosis. Furthermore, there is weak evidence that dense breast tissue may be an independent risk factor for breast cancer.2 Breast Density There is an increasing awareness that screening with mammography alone may not be enough in women with dense breasts. While breast MRI is recognized by the American Cancer Society as a complementary 6mm screening tool in women at very high risk for the development of breast cancer , due to it’s lower specificity, higher cost and limited accessibility, it has not been recommended in intermediate risk FATTY BREAST or dense breasted women. -
Double Reading of Automated Breast Ultrasound with Digital Mammography Or Digital Breast Tomosynthesis for Breast Cancer Screening T ⁎ Janie M
Clinical Imaging 55 (2019) 119–125 Contents lists available at ScienceDirect Clinical Imaging journal homepage: www.elsevier.com/locate/clinimag Breast Imaging Double reading of automated breast ultrasound with digital mammography or digital breast tomosynthesis for breast cancer screening T ⁎ Janie M. Leea, , Savannah C. Partridgea, Geraldine J. Liaoa, Daniel S. Hippea, Adrienne E. Kima, Christoph I. Leea, Habib Rahbara, John R. Scheela, Constance D. Lehmanb a University of Washington, Department of Radiology, Seattle Cancer Care Alliance, 825 Eastlake Avenue East, G2-600, Seattle, WA 98109-1023, United States of America b Massachusetts General Hospital, Department of Radiology, 15 Parkman St., Boston, MA 02114, United States of America ARTICLE INFO ABSTRACT Keywords: Purpose: To evaluate the impact of double reading automated breast ultrasound (ABUS) when added to full field Breast cancer screening digital mammography (FFDM) or digital breast tomosynthesis (DBT) for breast cancer screening. Automated breast ultrasound Methods: From April 2014 to June 2015, 124 women with dense breasts and intermediate to high breast cancer fi Full eld digital mammography risk were recruited for screening with FFDM, DBT, and ABUS. Readers used FFDM and DBT in clinical practice Digital breast tomosynthesis and received ABUS training prior to study initiation. FFDM or DBT were first interpreted alone by two in- dependent readers and then with ABUS. All recalled women underwent diagnostic workup with at least one year of follow-up. Recall rates were compared using the sign test; differences in outcomes were evaluated using Fisher's exact test. Results: Of 121 women with complete follow-up, all had family (35.5%) or personal (20.7%) history of breast cancer, or both (43.8%). -
Mammary Ductoscopy in the Current Management of Breast Disease
Surg Endosc (2011) 25:1712–1722 DOI 10.1007/s00464-010-1465-4 REVIEWS Mammary ductoscopy in the current management of breast disease Sarah S. K. Tang • Dominique J. Twelves • Clare M. Isacke • Gerald P. H. Gui Received: 4 May 2010 / Accepted: 5 November 2010 / Published online: 18 December 2010 Ó Springer Science+Business Media, LLC 2010 Abstract terms ‘‘ductoscopy’’, ‘‘duct endoscopy’’, ‘‘mammary’’, Background The majority of benign and malignant ‘‘breast,’’ and ‘‘intraductal’’ were used. lesions of the breast are thought to arise from the epithe- Results/conclusions Duct endoscopes have become lium of the terminal duct-lobular unit (TDLU). Although smaller in diameter with working channels and improved modern mammography, ultrasound, and MRI have optical definition. Currently, the role of MD is best defined improved diagnosis, a final pathological diagnosis cur- in the management of SND facilitating targeted surgical rently relies on percutaneous methods of sampling breast excision, potentially avoiding unnecessary surgery, and lesions. The advantage of mammary ductoscopy (MD) is limiting the extent of surgical resection for benign disease. that it is possible to gain direct access to the ductal system The role of MD in breast-cancer screening and breast via the nipple. Direct visualization of the duct epithelium conservation surgery has yet to be fully defined. Few allows the operator to precisely locate intraductal lesions, prospective randomized trials exist in the literature, and enabling accurate tissue sampling and providing guidance these would be crucial to validate current opinion, not only to the surgeon during excision. The intraductal approach in the benign setting but also in breast oncologic surgery. -
Prevalence of Breast Cancer in Patients Undergoing
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Wits Institutional Repository on DSPACE Prevalence of breast cancer in patients undergoing microdochectomy for a pathological nipple discharge Dr Chiapo Lesetedi AFRCSI(Dublin), FCS(SA) Student Number: 584356 Department of Surgery University of the Witwatersrand E-mail: [email protected] Cell No: 073 394 2043 Supervisors: Dr Sarah Rayne, MRCS, MMed(Wits), FCS(SA), Department of Surgery, University of the Witwatersrand Dr Deirdré Kruger, BSc, PGCHE, PhD(UK), Department of Surgery, University of the Witwatersrand 18th July 2016 Page 1 of 33 TABLE OF CONTENTS DECLARATION……………………………………………………….………………3 ACKNOWLEDGEMENTS……………………………………………………………4 ABSTRACT…………………………………………………………………………….5 CHAPTER 1: INTRODUCTION…………………………………………...…………7 CHAPTER 2: METHODS……………………………………………………..…….10 CHAPTER 3: RESULTS…………………………………………………………….13 CHAPTER 4: DISCUSSION………………………………………………….…….15 CHAPTER 5: REFERENCES………………………………………………………19 APPENDIX 1: APPROVED PROTOCOL………..………………………………..23 APPENDIX 2: DATA RECORDING SHEET…………………..………………….31 APPENDIX 3: ETHICS CLEARANCE……………………………………….……33 Page 2 of 33 DECLARATION I, Chiapo Lesetedi, declare that this research project is my own work. It is being submitted for the degree of Master of Medicine in Surgery at the University of the Witwatersrand, Johannesburg, South Africa. It is submitted by submissible paper format. It has not been submitted before for any degree or examination at this or any other University. ________________ Dr Chiapo Lesetedi 18th July 2016 Page 3 of 33 ACKNOWLEDGEMENTS I would like to thank my supervisors, Dr Sarah Rayne and Dr Deirdré Kruger, who guided me from the start and continuously encouraged and supported me during the writing up of this research project. They have tirelessly assisted in proof reading the project and Dr Kruger also assisted with data analysis and statistics involved.